Our French customers can now benefit from tax relief up to 30% on any eligible research and development (R&D) costs incurred with us.
The minister of higher education, research and innovation (MESRI) in France has approved CTC Clinical Trial Consultants AB to perform R&D services on behalf of third parties for the years 2020-2022.
"We are thrilled receiving this approval. Most of our services are now eligible for tax relief enabling more Life Science companies in France to conduct clinical trials in collaboration with us", says Fredrik Hansson, Chief Commercial Officer at CTC.
The CIR is a public aid for the development of research and business innovation. This tax measure grants a tax reduction calculated on the basis of R&D expenditure incurred by companies. It is deductible from the corporate tax due for the year in which the expenses were incurred and the rate of the tax credit granted to businesses is 30% of eligible expenses. Eligible services for the tax relief are research in investigational stages, for example clinical conduct, monitoring, data analysis as well as reporting the study outcome both as clinical study reports and manuscripts.
Enter your email address to follow CTC Clinical Trial Consultants AB